SCHEMBL29623487

SCHEMBL29623487

COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CCC(N2CCOC(=O)C2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 19/20 0.71
KDR P35968 2/20 0.66
EPHB4 P54760 2/20 0.66
CIT O14578 1/20 0.66
GAK O14976 1/20 0.66
EPHB6 O15197 1/20 0.66
ABCC4 O15439 1/20 0.66
DAPK3 O43293 1/20 0.66
RIPK2 O43353 1/20 0.66
NR1I2 O75469 1/20 0.66
RPS6KA4 O75676 1/20 0.66
STK17B O94768 1/20 0.66
STK10 O94804 1/20 0.66
PRKD3 O94806 1/20 0.66
ABCB11 O95342 1/20 0.66
MAP4K4 O95819 1/20 0.66
CHEK2 O96017 1/20 0.66
ABL1 P00519 1/20 0.66
ERBB2 P04626 1/20 0.66
LCK P06239 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL175222 1.00 EGFR (0.71) EGFRKDREPHB4CITGAK
SCHEMBL5230874 1.00 EGFR (0.71) EGFRKDREPHB4CITGAK
SCHEMBL5227742 0.97 EGFR (0.72) EGFRKDREPHB4CITGAK
SCHEMBL5229002 0.97 EGFR (0.72) EGFRKDREPHB4CITGAK
SCHEMBL5227344 0.91 EGFR (0.62) EGFRKDREPHB4CITGAK
SCHEMBL5224316 0.91 EGFR (0.62) EGFRKDREPHB4CITGAK
SCHEMBL5225680 0.90 EGFR (0.57) EGFRKDREPHB4CITGAK
SCHEMBL5226439 0.90 EGFR (0.60) EGFRKDREPHB4CITGAK
SCHEMBL5231564 0.90 EGFR (0.60) EGFRKDREPHB4CITGAK
SCHEMBL5229214 0.90 EGFR (0.57) EGFRKDREPHB4CITGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223294-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES Vertex Pharmaceuticals Incorporated (US) 2023-08-09 EP disclosed
CN-110840847-B Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases 沃泰克斯药物股份有限公司 2022-07-29 CN disclosed
CN-110713489-B Heteroaryl SYK inhibitors 勃林格殷格翰国际有限公司 2022-05-31 CN disclosed
CN-110183440-B Heteroaryl SYK inhibitors 勃林格殷格翰国际有限公司 2022-04-22 CN disclosed